A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral Therapy

Completed · Phase 3

Conditions studied: HIV Infections

In brief

The purpose of this clinical research study is to learn if atazanavir is associated with serum LDL cholesterol in HIV-infected subjects following a substitution of atazanavir for their previously administered protease inhibitor.

Key facts

Study ID: NCT00067782
Run by: Bristol-Myers Squibb
Starts: 2002-12-01
Expected to finish: 2005-03-01
Last updated by the study team: 2011-04-14

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Local Institution — Phoenix, Arizona, United States
Local Institution — West Hollywood, California, United States
Local Institution — Washington D.C., District of Columbia, United States
Local Institution — Altamonte Springs, Florida, United States
Local Institution — Fort Lauderdale, Florida, United States
Local Institution — Miami, Florida, United States
Local Institution — Tampa, Florida, United States
Local Institution — Boston, Massachusetts, United States
Local Institution — Minneapolis, Minnesota, United States
Local Institution — St Louis, Missouri, United States
Local Institution — East Orange, New Jersey, United States
Local Institution — New York, New York, United States
Local Institution — Huntersville, North Carolina, United States
Local Institution — Cleveland, Ohio, United States
Local Institution — Oklahoma City, Oklahoma, United States
Local Institution — Philadelphia, Pennsylvania, United States
Local Institution — Columbia, South Carolina, United States
Local Institution — Fort Worth, Texas, United States
Local Institution — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.